Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 351-357

  Wong, Pancras C ^a   Quan, Mimi L ^a   Crain, Earl J ^a   Watson, Carol A ^a   Wexler, Ruth R ^a   Knabb, Robert M ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [(2' AMINOSULFONYL 1,1' BIPHENYL 4 YL)CARBAMOYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; HEPARIN; ISOXAZOLINE DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENANTIOMER; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; ISOXAZOLES; MALE; NAPHTHALENES; PLATELET AGGREGATION; PROPIONIC ACIDS; RABBITS; RECOMBINANT PROTEINS; SULFONAMIDES; TETRAZOLES; THROMBOSIS;

EID: 0033957888     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cody RP and Smith JK (1991) Applied Statistics and the SAS Programming Language, 3rd ed., Prentice Hall, Englewood Cliffs, NJ.
2. Dunn CJ and Sorkin EM (1996) Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs 52:276-305.
3. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T and Iwamoto M (1994) DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemostasia 71:314-319.
4. Hara T, Yokoyama A, Morishima Y and Kunitada S (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80:99-104.
5. Harker LA, Hanson SR and Kelly AB (1997) Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemostasis 78:736-741.
6. Hauptmann J and Stürzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb Res 93:203-241.
7. Kaiser B (1998) Thrombin and factor Xa inhibitors. Drugs Future 23:423-436.
8. Kettner C, Mersinger L and Knabb R (1990) The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 265:18289-18297.
9. Kher A, Al Dieri R, Hemker HC and Béguin S (1997) Laboratory assessment of antithrombotic therapy: What tests and if so why? Haemostasia 27:211-218.
10. Nagahara T, Katakura S, Inanmura K, Komoriya S., Hara T, Kunitada S, Yokoyama Y, Yamazaki K and Iwamoto M (1995) DX-9065A. Drugs Future 20:564-566.
11. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardina M, Ellis RW, Schaffer LW, Siegl PKS and Vlasuk GP (1990) Characterization of recombinant tick anti-coagulant peptide. J Biol Chem 265:17746-17752.
12. Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD and Wallis RB (1991) The characterization of thrombus development in an improved model of arterio-venous thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemostasis 65:268-274.
13. Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G, Wright MR, Wong PC and Wexler RR (1999a) Design and synthesis of isoxazoline derivatives as factor Xa Inhibitors. 2. J Med Chem 42:2760-2773.
14. Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL, Huang PP, Harrison K, Knabb RM, Thoolen MJ, Wong PC and Wexler RR (1999b) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. J Med Chem 42: 2752-2759.
15. Quan ML, Pruitt JR, Ellis CD, Lauw AY, Galemmo RA, Stouten PFW, Wityak J, Knabb RM, Thoolen MJ, Wong PC and Wexler RR (1997) Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 7:2813-2818.
16. Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H and Matsumoto Y (1998) Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 347:231-236.
17. Taniuchi Y, Sakai Y, Hisamichi N, Kayama M, Mano Y, Sato K, Hirayama F, Koshio H, Matsumoto Y and Kawasaki T (1998) Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemostasis 79:543-548.
18. Turpie AGG (1998) Pharmacology of the low-molecular-weight heparins. Am Heart J 135:S329-S335.
19. Wong PC, Crain EJ, Nguan O, Watson CA and Racanelli A (1996) Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 83:117-126.